BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24452717)

  • 1. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.
    Ling XH; Han ZD; Xia D; He HC; Jiang FN; Lin ZY; Fu X; Deng YH; Dai QS; Cai C; Chen JH; Liang YX; Zhong WD; Wu CL
    Mol Biol Rep; 2014 May; 41(5):2779-88. PubMed ID: 24452717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
    Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
    Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer.
    Xiong SW; Lin TX; Xu KW; Dong W; Ling XH; Jiang FN; Chen G; Zhong WD; Huang J
    Pathol Oncol Res; 2013 Jul; 19(3):529-37. PubMed ID: 23456549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer.
    Chiyomaru T; Yamamura S; Fukuhara S; Hidaka H; Majid S; Saini S; Arora S; Deng G; Shahryari V; Chang I; Tanaka Y; Tabatabai ZL; Enokida H; Seki N; Nakagawa M; Dahiya R
    PLoS One; 2013; 8(3):e58929. PubMed ID: 23554959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.
    Lin ZY; Huang YQ; Zhang YQ; Han ZD; He HC; Ling XH; Fu X; Dai QS; Cai C; Chen JH; Liang YX; Jiang FN; Zhong WD; Wang F; Wu CL
    Int J Cancer; 2014 Aug; 135(3):541-50. PubMed ID: 24382668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Guan Y; Wu Y; Liu Y; Ni J; Nong S
    Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer.
    Liang YK; Han ZD; Lu JM; Liu ZZ; Zhuo YJ; Zhu XJ; Chen JX; Ye JH; Liang YX; He HC; Zhong WD
    J Cell Biochem; 2018 Sep; 119(9):7245-7255. PubMed ID: 29797600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
    Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
    Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
    Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
    Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.
    Avgeris M; Stravodimos K; Fragoulis EG; Scorilas A
    Br J Cancer; 2013 Jun; 108(12):2573-81. PubMed ID: 23703249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.
    Wan Y; Zeng ZC; Xi M; Wan S; Hua W; Liu YL; Zhou YL; Luo HW; Jiang FN; Zhong WD
    Hum Pathol; 2015 Feb; 46(2):295-303. PubMed ID: 25532941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.
    Lin ZY; Chen G; Zhang YQ; He HC; Liang YX; Ye JH; Liang YK; Mo RJ; Lu JM; Zhuo YJ; Zheng Y; Jiang FN; Han ZD; Wu SL; Zhong WD; Wu CL
    Mol Cancer; 2017 Feb; 16(1):48. PubMed ID: 28241827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
    Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
    Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma.
    Huang Z; Zhang L; Yi X; Yu X
    Tumour Biol; 2016 Apr; 37(4):4359-65. PubMed ID: 26499781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer.
    Lai YH; Chen J; Wang XP; Wu YQ; Peng HT; Lin XH; Wang WJ
    J Exp Clin Cancer Res; 2017 Jul; 36(1):92. PubMed ID: 28697793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-326 functions as a tumor suppressor in human prostatic carcinoma by targeting Mucin1.
    Liang X; Li Z; Men Q; Li Y; Li H; Chong T
    Biomed Pharmacother; 2018 Dec; 108():574-583. PubMed ID: 30243091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [miR-129 in the diagnosis, treatment and prediction of clinical prognosis of prostate cancer].
    Zhao XD; Tang ZL; Wang ZH; Dong J; Xu S
    Zhonghua Nan Ke Xue; 2022 Nov; 28(11):996-1005. PubMed ID: 37846115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-1273 g-3p Promotes Malignant Progression and has Prognostic Implications in Prostate Cancer.
    Chang Y; Deng Q; Guan Z; Cheng Y; Sun Y
    Mol Biotechnol; 2022 Jan; 64(1):17-24. PubMed ID: 34431044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.